Table 4.
Active Trials of Disease-Modifying Therapy for Cerebrovascular Disease in the United States
| ID | Drug | Design | Outcome | Ages (Years) | Sponsor |
|---|---|---|---|---|---|
| NCT04218084 | Voxelotor | RCT | TCD | 2 to 14 | Global Blood Therapeutics |
| NCT05228834 | RCT | Neurocognition | 8 to 17 | Global Blood Therapeutics | |
| NCT02850406 | Single-arm | Pharmacokinetics, hemoglobin, TCD | 0.5 to 17 | Global Blood Therapeutics | |
| NCT05018728 | Single-arm | Hemodynamics | 4 to 17 | Robert Clark Brown | |
| NCT05334576 | Crizanlizumab | Single-arm | SCI | 16 and older | Andria Ford |
Abbreviations: ID, ClinicalTrials.gov Identification Number; RCT, randomized controlled trial; TCD, transcranial Doppler; SCI, silent cerebral infarction.